货号:A125368
同义名:
SAG hydrochloride
SAG HCl是一种高效的 Smoothened (Smo) 受体激动剂 (EC50=3 nM; Kd=59 nM),可激活 Hedgehog 信号通路,并抵消 Cyclopamine 对 Smo 的抑制。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 描述 | SAG hydrochloride is a highly effective agonist of the Smoothened (Smo) receptor (EC50=3 nM; KD=59 nM). It activates the Hedgehog signaling pathway and antagonizes the inhibitory effects of Cyclopamine on Smo[1][2][3]. |
| 体内研究 | SAG (1.0 mM) primarily promotes osteogenesis, particularly at the borders of defects, and leads to a significant increase in BV/TV at the eight-week time point in CD-1 mice[4]. |
| Concentration | Treated Time | Description | References | |
| Primary hepatic cells | 0.25–2.00 mM | 1 h | SAG pre-treatment significantly protected against cytotoxicity induced by CCl4 and significantly reduced AST and ALT levels. | Int J Mol Sci. 2022 Apr 17;23(8):4429. |
| human adipose-derived mesenchymal stem cells (ASCs) | 200 nM | 24 h | Activate the Hedgehog signaling pathway and detect the accumulation of Smo in cilia. Results showed that SAG treatment increased the accumulation of Smo in cilia, indicating the activation of the Hedgehog pathway. | Stem Cell Reports. 2018 Feb 13;10(2):583-599. |
| NIH 3T3 cells | 1 μM | 48 h | To detect defects in downstream Shh signaling in Chmp1a null and control MEFs, measured by Gli1 activation, showing no significant defect. | Cell Rep. 2018 Jul 24;24(4):973-986.e8. |
| SVG-A cells | 1 μM | 48 h | Activation of SHH signaling, inducing GLI1 and PTCH expression, showing no significant difference between CHMP1A null and WT cells. | Cell Rep. 2018 Jul 24;24(4):973-986.e8. |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | Ick-mutant mice | Intraperitoneal injection | 20 mg/kg | Single injection, embryos harvested between E12.5 and E18.5 | By activating the SHH signaling pathway, SAG treatment successfully rescued congenital defects in Ick-mutant mice, including cleft palate. | EBioMedicine. 2019 Nov;49:305-317 |
| BALB/c mice | Listeria infection model | Subcutaneous injection | 50 µg,100 μL | Booster immunization 3 weeks after the first immunization | To evaluate the immunological response and protective efficacy of archaeosome-encapsulated SAgs in BALB/c mice, the results showed that archaeosome-encapsulated SAgs significantly upregulated Th1 cytokine production and reduced bacterial burden in infected mice. | Int J Nanomedicine. 2012;7:2433-47 |
| Mice | Cfp1d/d mouse model | Intrauterine injection | 1000 nM,10 μL | Single injection, sacrificed at 3 or 21 hours | SAG successfully rescued aberrant uterine cell proliferation and gene expression in Cfp1d/d female mice. | Nat Commun. 2023 Jun 3;14(1):3220 |
| Mice | MCAo model | Gavage | 10mg/kg | Once daily for 6 days | To evaluate the role of SAG in post-stroke functional recovery, results showed that SAG treatment significantly improved motor and cognitive functions and increased the survival of newly generated cells. | Stroke. 2017 Jun;48(6):1636-1645 |
| Mice | CCl4-induced liver injury model | Oral | 30 mg/kg | Twice a week for 8 weeks | SAG significantly restored SOD activity, GSH levels, and GPx activity, while it strongly reduced GSSG levels, lipid peroxidation, and H2O2 and ROS levels. SAG also reduced inflammation and fibrosis, improved liver function and mitophagy. | Int J Mol Sci. 2022 Apr 17;23(8):4429. |
| Dose | Mice: 15 mg/kg - 20 mg/kg[3] (i.p.) |
| Administration | i.p. |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.90mL 0.38mL 0.19mL |
9.50mL 1.90mL 0.95mL |
18.99mL 3.80mL 1.90mL |
|
| CAS号 | 2095432-58-7 |
| 分子式 | C28H29Cl2N3OS |
| 分子量 | 526.52 |
| SMILES Code | O=C(C1=C(Cl)C2=CC=CC=C2S1)N([C@H]3CC[C@H](NC)CC3)CC4=CC=CC(C5=CC=NC=C5)=C4.[H]Cl |
| MDL No. | N/A |
| 别名 | SAG hydrochloride |
| 运输 | 蓝冰 |
| InChI Key | CRWTYWYPPITOOZ-UHFFFAOYSA-N |
| Pubchem ID | 121540649 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Inert atmosphere, 2-8°C |
| 溶解方案 |
DMSO: 20 mg/mL(37.99 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO H2O: 25 mg/mL(47.48 mM),配合低频超声助溶 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1